Sunitinib and other targeted therapies for renal cell carcinoma

Targeted therapy has radically altered the way metastatic renal cancer is treated. Six drugs are now licensed in this setting, with several other agents under evaluation. Sunitinib is currently the most widely used in the first line setting with impressive efficacy and an established toxicity profil...

Descripción completa

Detalles Bibliográficos
Autores principales: Powles, T, Chowdhury, S, Jones, R, Mantle, M, Nathan, P, Bex, A, Lim, L, Hutson, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048200/
https://www.ncbi.nlm.nih.gov/pubmed/21266975
http://dx.doi.org/10.1038/sj.bjc.6606061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048200/
https://www.ncbi.nlm.nih.gov/pubmed/21266975
http://dx.doi.org/10.1038/sj.bjc.6606061

Ejemplares similares